2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10869
    OL-135 681135-77-3 98%
    OL-135 is a CNS penetrant, selective, and reversible of FAAH inhibitor. OL-135 exhibits analgesic activity.
    OL-135
  • HY-11085
    T-226296 331758-35-1 98%
    T-226296 is an oral active and selective melanin-concentrating hormone receptor antagonist with the IC50 values of 5.5 nM and 8.6 nM for human SLC-1 and rat SLC-1, respectively. T-226296 can be used for study of obesity and insulin resistance.
    T-226296
  • HY-12074
    Cazpaullone 914088-64-5 98%
    Cazpaullone is a glycogen synthase kinase-3 (GSK-3) inhibitor. Cazpaullone can activate pancreatic beta cell protection and replication. Cazpaullone can be used for the research of diabetes.
    Cazpaullone
  • HY-12104
    PF-514273 851728-60-4 98%
    PF-514273 is an orally active, selective antagonist for cannabinoid-1 receptor (CB1) with IC50 of 1 nM. PF-514273 reduces the food uptake in mice, and can be used for obesity research.
    PF-514273
  • HY-12735
    SCH 900822 1220894-09-6 98%
    SCH 900822 is a potent and selective glucagon receptor (hGCGR) antagonist that blocks the binding of glucagon to its receptor, thereby reducing hepatic glycogenolysis and gluconeogenesis, thereby lowering blood glucose production. SCH 900822 can be used in the study of type 2 diabetes.
    SCH 900822
  • HY-12976
    DS-1558 1202575-67-4 98%
    DS-1558 is an orally active small molecule G protein-coupled receptor 40 agonist. DS-1558 not only increases the glucose-stimulated insulin secretion by glucagon like peptide-1 (GLP-1) but also potentiated the maximum insulinogenic effects of GLP-1 after an intravenous glucose injection in normal Sprague Dawley rats. DS-1558 is promising for research of type 2 diabetes.
    DS-1558
  • HY-14156
    11β-HSD1-IN-15 946398-78-3 98%
    11β-HSD1-IN-15 is an inhibitor of 11β-hydroxysteroid dehydrogenase type I (11β-HSD1). 11β-HSD1-IN-15 blocks the conversion of corticosterone to cortisol by binding to the active site of the 11β-HSD1 enzyme. 11β-HSD1-IN-15 can be used to investigate the role of 11β-HSD1 enzymes IN the development of metabolic syndrome, obesity, cognitive decline and type 2 diabetes.
    11β-HSD1-IN-15
  • HY-14747
    Piragliatin 625114-41-2 98%
    Piragliatin (RO4389620) is an activator for glucokinase, which reduces endogenous glucose production, increases β-cell function and glucose utilization, and thus decreases the blood glucose levels. Piragliatin exhibits antidiabetic efficacy.
    Piragliatin
  • HY-15384
    Picoprazole 78090-11-6 98%
    Picoprazole is a specific inhibitor of H+/K+-ATPase with IC50 of 3.1±0.4 μM.
    Picoprazole
  • HY-16266
    JNJ-DGAT1-A 1092067-85-0 98%
    JNJ-DGAT1-A is a selective DGAT1 inhibitor. JNJ-DGAT1-A inhibits DGAT1 activity and TG synthesis.
    JNJ-DGAT1-A
  • HY-16304
    Mannose 1-phosphate 27251-84-9 98%
    Mannose 1-phosphate is a phosphorylated mannose that serves as a precursor of GDP-mannose, a constituent unit of glycosylation biosynthetic pathways. Mannose 1-phosphate increases intracellular GDP-mannose concentration, promotes normalization of lipid-linked oligosaccharide structures, and enhances the formation of mature N-glycans on cellular proteins. Mannose 1-phosphate can be used in studies related to glycosylation disorders.
    Mannose 1-phosphate
  • HY-16708
    ZLN024 723249-01-2 98%
    ZLN024 is an AMPK allosteric activator. ZLN024 directly activates recombinant AMPK α1β1γ1, AMPK α2β1γ1, AMPK α1β2γ1 and AMPK α2β2γ1 heterotrimer with EC50s of 0.42 µM, 0.95 µM, 1.1 µM and 0.13 µM, respectively.
    ZLN024
  • HY-17669
    PSB-16434 2189700-02-3
    PSB-16434 is a selective G protein-coupled receptor 84 (GPR84) agonist. PSB-16434 is promising for research of inflammatory diseases, metabolic disorders, and immune regulation.
    PSB-16434
  • HY-18057
    BVT-3498 376641-49-5 98%
    BVT-3498 (AMG-311) is an inhibitor for 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
    BVT-3498
  • HY-18903
    DSA8 1157857-37-8 98%
    DSA8 is a type II kinase inhibitor with IRE1 RNase modulating activity. DSA8 can be used for the research of cancer, metabolic disease, suah as diabetes.
    DSA8
  • HY-19030
    TA-1801 88352-44-7 98%
    TA-1801 is a hypolipidemic agent.
    TA-1801
  • HY-19083
    SIM-6080 118790-68-4 98%
    SIM-6080 is a calcium antagonist and inhibits the proliferation of rat aortic myocytes and reduces aortic atherosclerosis in rabbits.
    SIM-6080
  • HY-19164
    BOF-4272 142181-44-0 98%
    BOF-4272 is a xanthine oxidase/xanthine dehydrogenase inhibitor. BOF-4272 can be used for hyperuricemia research.
    BOF-4272
  • HY-19218
    RPR-106541 159001-35-1 98%
    RPR-106541 is a 17-thiosteroid. RPR 106541 has potent glucocorticosteroid activity. RPR 106541 also has demonstrable effects on carbohydrate and lipid metabolism.
    RPR-106541
  • HY-19394
    CLX-0921 249886-47-3 98%
    CLX-0921 is an orally active PPARγ agonist with an IC50 of 1.54 μM. CLX-0921 has a potent antihyperglycemic activity, and can be used for the study of type 2 diabetes.
    CLX-0921
Cat. No. Product Name / Synonyms Application Reactivity